Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | F13A1 | P00488 | 4/20 | 0.50 |
| ▸ | TGM2 | P21980 | 4/20 | 0.50 |
| ▸ | TGM1 | P22735 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084704 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL2492947 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL28408148 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL21806124 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL711419 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL375302 | 0.93 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL18592896 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL504558 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL3620573 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 | |
| SCHEMBL16095295 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20250333397-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023034836-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-8153635-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8030501-B2 | Process for producing optically active 3-amino nitrogen-containing compounds | KANEKA CORPORATION (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20090326246-A1 | Method for Production of Optically Active 3-Amino-Nitrogenated Compound | KANEKA CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| EP-2050735-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-NITROGENATED COMPOUND | Kaneka Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333397-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | SMN1; SMN2 301/4885NPC1 1905/4885RAB9A 3354/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | SMN1; SMN2 3996/4885NPC1 2080/4885RAB9A 45/4885 |
| US-20090326246-A1 | Method for Production of Optically Active 3-Amino-Nitrogenated Compound | PNMT, NPEPPS, GNMT | SMN1; SMN2 992/4885NPC1 2790/4885RAB9A 1721/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | SMN1; SMN2 2800/4885NPC1 298/4885RAB9A 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.